Hepatocellular Carcinoma - Market Insights, Epidemiology and Market Forecast-2027
This report can be delivered to the clients within 24 Hours
DelveInsight’s ‘Hepatocellular Carcinoma - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of HCC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), China and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Hepatocellular Carcinoma from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan
China
Study Period: 2016-2027
Hepatocellular Carcinoma - Disease Understanding and Treatment Algorithm
The DelveInsight Hepatocellular Carcinoma market report gives the thorough understanding of the Hepatocellular Carcinoma by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hepatocellular Carcinoma in the US, EU5, China and Japan.
Hepatocellular Carcinoma Epidemiology
The Hepatocellular Carcinoma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident cases, diagnosed advanced HCC and patients by line of therapies) scenario of Hepatocellular Carcinoma in the G8 countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), China and Japan from 2016-2027.
According to DelveInsight, the total number of incident cases of Hepatocellular Carcinoma was found to be 458,170, in the year 2016 in G8 countries.
Hepatocellular Carcinoma Drug Chapters
This segment of the Hepatocellular Carcinoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the therapeutic market size of HCC is primarily dominated by the protein Kinase inhibitor i.e., Nexavar [Sorafenib; Bayer] which is the first line of therapy followed by the off-label systemic chemotherapies being used as second line of treatment for managing the disease. However, Opdivo (Bristol-Myers Squibb) and Stivarga (Bayer), both have received the FDA approval in 2017 itself and both of them are also contributing towards the HCC market revenue. Detailed chapter for upcoming therapies like Lenvima (Merck/Eisai), Ramucirumab (Cyramza) (Eli Lily and Co.) and Cabometyx (Exelixis Inc.) have been covered in the report.
Hepatocellular Carcinoma Market Outlook
The Hepatocellular Carcinoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Hepatocellular Carcinoma in G8 countries was found to be USD 723.4 million in 2016.
Hepatocellular Carcinoma Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Hepatocellular Carcinoma Report Insights
DelveInsight’s ‘Hepatocellular Carcinoma - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of HCC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), China and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Hepatocellular Carcinoma from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan
China
Study Period: 2016-2027
Hepatocellular Carcinoma - Disease Understanding and Treatment Algorithm
The DelveInsight Hepatocellular Carcinoma market report gives the thorough understanding of the Hepatocellular Carcinoma by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hepatocellular Carcinoma in the US, EU5, China and Japan.
Hepatocellular Carcinoma Epidemiology
The Hepatocellular Carcinoma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident cases, diagnosed advanced HCC and patients by line of therapies) scenario of Hepatocellular Carcinoma in the G8 countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), China and Japan from 2016-2027.
According to DelveInsight, the total number of incident cases of Hepatocellular Carcinoma was found to be 458,170, in the year 2016 in G8 countries.
Hepatocellular Carcinoma Drug Chapters
This segment of the Hepatocellular Carcinoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the therapeutic market size of HCC is primarily dominated by the protein Kinase inhibitor i.e., Nexavar [Sorafenib; Bayer] which is the first line of therapy followed by the off-label systemic chemotherapies being used as second line of treatment for managing the disease. However, Opdivo (Bristol-Myers Squibb) and Stivarga (Bayer), both have received the FDA approval in 2017 itself and both of them are also contributing towards the HCC market revenue. Detailed chapter for upcoming therapies like Lenvima (Merck/Eisai), Ramucirumab (Cyramza) (Eli Lily and Co.) and Cabometyx (Exelixis Inc.) have been covered in the report.
Hepatocellular Carcinoma Market Outlook
The Hepatocellular Carcinoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Hepatocellular Carcinoma in G8 countries was found to be USD 723.4 million in 2016.
Hepatocellular Carcinoma Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Hepatocellular Carcinoma Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- G8 Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Hepatocellular Carcinoma market
- Organize sales and marketing efforts by identifying the best opportunities for Hepatocellular Carcinoma market
- To understand the future market competition in the Hepatocellular Carcinoma market
1. KEY INSIGHTS
2. HEPATOCELLULAR CARCINOMA MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of Hepatocellular Carcinoma in 2016
2.2. Market Share (%) Distribution of Hepatocellular Carcinoma in 2027
3. DISEASE BACKGROUND AND OVERVIEW: HEPATOCELLULAR CARCINOMA
3.1. Introduction
3.2. Signs and Symptoms
3.3. Staging of Hepatocellular Carcinoma
3.3.1. Okuda Stage
3.3.2. French Classification
3.3.3. CLIP Score
3.3.4. CUPI Score
3.3.5. TNM Stage
3.3.6. JIS Staging
3.3.7. BCLC Staging System
3.4. Etiology and Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.6.1. AASLD practice guidelines for HCC surveillance and diagnosis
3.6.2. EASL-EORTC practice guidelines for HCC surveillance and diagnosis
3.6.3. Japanese evidence-based clinical practice guidelines for HCC
3.6.4. NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines
4. EPIDEMIOLOGY AND PATIENT POPULATION
5. KEY FINDINGS
6. POPULATION AND FORECAST PARAMETERS
6.1. Total Incident Cases of HCC in G8 countries
6.2. Total Diagnosed Advanced HCC cases in G8 countries
6.3. Total Patients on First-Line Therapies
6.4. Total Patients on Second-Line Therapies
7. COUNTRY WISE-EPIDEMIOLOGY OF HCC
7.1. United States
7.1.1. Total Incident cases of HCC in the United States
7.1.2. Total Diagnosed Advanced HCC cases in the United States
7.1.3. Total Patients on Therapies
7.1.4. Total Patients By Line of Therapies in the United States
7.2. EU5 Countries
7.3. Germany
7.3.1. Total Incident cases of HCC in Germany
7.3.2. Total Diagnosed Advanced HCC cases in Germany
7.3.3. Total Patients on Therapies
7.3.4. Total Patients By Line of Therapies in Germany
7.4. France
7.4.1. Total Incident cases of HCC in France
7.4.2. Total Diagnosed Advanced HCC cases in the France
7.4.3. Total Patients on Therapies
7.4.4. Total Patients By Line of Therapies in France
7.5. Italy
7.5.1. Total Incident cases of HCC in Italy
7.5.2. Total Diagnosed Advanced HCC cases in Italy
7.5.3. Total Patients on Therapies
7.5.4. Total Patients By Line of Therapies in Italy
7.6. Spain
7.6.1. Total Incident cases of HCC in Spain
7.6.2. Total Diagnosed Advanced HCC cases in Spain
7.6.3. Total Patients on Therapies
7.6.4. Total Patients By Line of Therapies in Spain
7.7. United Kingdom
7.7.1. Total Incident cases of HCC in the United Kingdom
7.7.2. Total Diagnosed Advanced HCC cases in the United Kingdom
7.7.3. Total Patients on Therapies
7.7.4. Total Patients By Line of Therapies in the UK
7.8. Japan
7.8.1. Total Incident cases of HCC in Japan
7.8.2. Total Diagnosed Advanced HCC cases in Japan
7.8.3. Total Patients on Therapies
7.8.4. Total Patients By Line of Therapies in Japan
7.9. China
7.9.1. Total Incident cases of HCC in China
7.9.2. Total Diagnosed Advanced HCC cases in China
7.9.3. Total Patients on Therapies
7.9.4. Total Patients By Line of Therapies in China
8. TREATMENT PRACTICES
8.1. Treatment Goals
8.2. Treatment Algorithm based on NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines for Treatment
8.3. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma
9. UNMET NEEDS
10. MARKETED DRUG ANALYSIS
10.1. Nexavar: Bayer HealthCare
10.1.1. Drug Description
10.1.2. Regulatory Milestones
10.1.3. Generic Availability
10.1.4. Advantages & Disadvantages
10.1.5. Clinical Development
10.1.6. Safety and Efficacy
10.1.7. Product Profile
10.2. Miripla: Sumitomo Dainippon Pharma
10.2.1. Drug Description
10.2.2. Regulatory Milestones
10.2.3. Clinical Development
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. Opdivo: Bristol-Myers Squibb
10.3.1. Drug Description
10.3.2. Regulatory Milestones
10.3.3. Advantages & Disadvantages
10.3.4. Clinical Development
10.3.5. Safety and Efficacy
10.3.6. Product Profile
10.4. Stivagra: Bayer Pharma
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Generic Availability
10.4.4. Advantages & Disadvantages
10.4.5. Clinical Development
10.4.6. Safety and Efficacy
10.4.7. Product Profile
11. EMERGING THERAPIES
12. EMERGING DRUGS ANALYSIS
12.1. Lenvima: Merck/Eisai
12.1.1. Drug Description
12.1.2. Regulatory Milestones
12.1.3. Advantages & Disadvantages
12.1.4. Clinical Development
12.1.5. Safety and Efficacy
12.1.6. Product Profile
12.2. Ramucirumab (Cyramza): Eli Lilly and Co.
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
12.3. Cabometyx: Exelixis Inc.
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Product Profile
13. OTHER PROMISING CANDIDATES
13.1. Milciclib: Tiziana Life Sciences
13.1.1. Product Description
13.1.2. Other Developmental Activities
13.1.3. Clinical Development
13.1.4. Safety and Efficacy
13.1.5. Product Profile
13.2. Capmatinib: Eli Lilly and Co.
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.2.5. Product Profile
13.3. Palbociclib: Pfizer
13.3.1. Product Description
13.3.2. Clinical Development
13.3.3. Safety and Efficacy
13.3.4. Product Profile
13.4. ENMD2076: CASI Pharmaceuticals
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Safety and Efficacy
13.4.5. Product Profile
14. FAILURE IN PHASE III CLINICAL TRIALS FOR HEPATOCELLULAR CARCINOMA
15. HEPATOCELLULAR CARCINOMA [HCC]: G8 COUNTRIES MARKET ANALYSIS
16. KEY FINDINGS
16.1. Total Market Size of Hepatocellular Carcinoma (HCC) in G8 Countries
16.2. G8 Countries Market Size of HCC by Line of Therapies
16.3. G8 Countries Market Size of HCC by Therapies
17. MARKET OUTLOOK BY COUNTRY
17.1. The United States: Market Outlook
17.1.1. United States Market Size
17.1.2. Total Market size of Hepatocellular carcinoma [HCC]
17.1.3. Hepatocellular Carcinoma Market Size by Line of Therapies
17.1.4. Market Size by First Line of Therapies
17.1.5. Market Size by Second Line of Therapies
17.2. EU-5 Countries: Market Outlook
17.3. Germany
17.3.1. Total Market size of Hepatocellular Carcinoma
17.3.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.3.3. Market Size by First Line of Therapies
17.3.4. Market Size by Second Line of Therapies
17.4. France
17.4.1. Total Market size of Hepatocellular Carcinoma
17.4.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.4.3. Market Size by First Line of Therapies
17.4.4. Market Size by Second Line of Therapies
17.5. Italy
17.5.1. Total Market size of Hepatocellular Carcinoma
17.5.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.5.3. Market Size by First Line of Therapies
17.5.4. Market Size by Second Line of Therapies
17.6. Spain
17.6.1. Total Market size of Hepatocellular Carcinoma
17.6.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.6.3. Market Size by First Line of Therapies
17.6.4. Market Size by Second Line of Therapies
17.7. United Kingdom
17.7.1. Total Market size of Hepatocellular Carcinoma
17.7.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.7.3. Market Size by First Line of Therapies
17.7.4. Market Size by Second Line of Therapies
17.8. Japan: Market Outlook
17.8.1. Total Market size of Hepatocellular Carcinoma
17.8.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.8.3. Market Size by First Line of Therapies
17.8.4. Market Size by Second Line of Therapies
17.9. China: Market Outlook
17.9.1. Total Market size of Hepatocellular Carcinoma
17.9.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.9.3. Market Size by First Line of Therapies
17.9.4. Market Size by Second Line of Therapies
18. MARKET DRIVERS
19. MARKET BARRIERS
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Sources Used
22. DELVEINSIGHT CAPABILITIES
23. DISCLAIMER
24. ABOUT DELVEINSIGHT
2. HEPATOCELLULAR CARCINOMA MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of Hepatocellular Carcinoma in 2016
2.2. Market Share (%) Distribution of Hepatocellular Carcinoma in 2027
3. DISEASE BACKGROUND AND OVERVIEW: HEPATOCELLULAR CARCINOMA
3.1. Introduction
3.2. Signs and Symptoms
3.3. Staging of Hepatocellular Carcinoma
3.3.1. Okuda Stage
3.3.2. French Classification
3.3.3. CLIP Score
3.3.4. CUPI Score
3.3.5. TNM Stage
3.3.6. JIS Staging
3.3.7. BCLC Staging System
3.4. Etiology and Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.6.1. AASLD practice guidelines for HCC surveillance and diagnosis
3.6.2. EASL-EORTC practice guidelines for HCC surveillance and diagnosis
3.6.3. Japanese evidence-based clinical practice guidelines for HCC
3.6.4. NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines
4. EPIDEMIOLOGY AND PATIENT POPULATION
5. KEY FINDINGS
6. POPULATION AND FORECAST PARAMETERS
6.1. Total Incident Cases of HCC in G8 countries
6.2. Total Diagnosed Advanced HCC cases in G8 countries
6.3. Total Patients on First-Line Therapies
6.4. Total Patients on Second-Line Therapies
7. COUNTRY WISE-EPIDEMIOLOGY OF HCC
7.1. United States
7.1.1. Total Incident cases of HCC in the United States
7.1.2. Total Diagnosed Advanced HCC cases in the United States
7.1.3. Total Patients on Therapies
7.1.4. Total Patients By Line of Therapies in the United States
7.2. EU5 Countries
7.3. Germany
7.3.1. Total Incident cases of HCC in Germany
7.3.2. Total Diagnosed Advanced HCC cases in Germany
7.3.3. Total Patients on Therapies
7.3.4. Total Patients By Line of Therapies in Germany
7.4. France
7.4.1. Total Incident cases of HCC in France
7.4.2. Total Diagnosed Advanced HCC cases in the France
7.4.3. Total Patients on Therapies
7.4.4. Total Patients By Line of Therapies in France
7.5. Italy
7.5.1. Total Incident cases of HCC in Italy
7.5.2. Total Diagnosed Advanced HCC cases in Italy
7.5.3. Total Patients on Therapies
7.5.4. Total Patients By Line of Therapies in Italy
7.6. Spain
7.6.1. Total Incident cases of HCC in Spain
7.6.2. Total Diagnosed Advanced HCC cases in Spain
7.6.3. Total Patients on Therapies
7.6.4. Total Patients By Line of Therapies in Spain
7.7. United Kingdom
7.7.1. Total Incident cases of HCC in the United Kingdom
7.7.2. Total Diagnosed Advanced HCC cases in the United Kingdom
7.7.3. Total Patients on Therapies
7.7.4. Total Patients By Line of Therapies in the UK
7.8. Japan
7.8.1. Total Incident cases of HCC in Japan
7.8.2. Total Diagnosed Advanced HCC cases in Japan
7.8.3. Total Patients on Therapies
7.8.4. Total Patients By Line of Therapies in Japan
7.9. China
7.9.1. Total Incident cases of HCC in China
7.9.2. Total Diagnosed Advanced HCC cases in China
7.9.3. Total Patients on Therapies
7.9.4. Total Patients By Line of Therapies in China
8. TREATMENT PRACTICES
8.1. Treatment Goals
8.2. Treatment Algorithm based on NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines for Treatment
8.3. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma
9. UNMET NEEDS
10. MARKETED DRUG ANALYSIS
10.1. Nexavar: Bayer HealthCare
10.1.1. Drug Description
10.1.2. Regulatory Milestones
10.1.3. Generic Availability
10.1.4. Advantages & Disadvantages
10.1.5. Clinical Development
10.1.6. Safety and Efficacy
10.1.7. Product Profile
10.2. Miripla: Sumitomo Dainippon Pharma
10.2.1. Drug Description
10.2.2. Regulatory Milestones
10.2.3. Clinical Development
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. Opdivo: Bristol-Myers Squibb
10.3.1. Drug Description
10.3.2. Regulatory Milestones
10.3.3. Advantages & Disadvantages
10.3.4. Clinical Development
10.3.5. Safety and Efficacy
10.3.6. Product Profile
10.4. Stivagra: Bayer Pharma
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Generic Availability
10.4.4. Advantages & Disadvantages
10.4.5. Clinical Development
10.4.6. Safety and Efficacy
10.4.7. Product Profile
11. EMERGING THERAPIES
12. EMERGING DRUGS ANALYSIS
12.1. Lenvima: Merck/Eisai
12.1.1. Drug Description
12.1.2. Regulatory Milestones
12.1.3. Advantages & Disadvantages
12.1.4. Clinical Development
12.1.5. Safety and Efficacy
12.1.6. Product Profile
12.2. Ramucirumab (Cyramza): Eli Lilly and Co.
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
12.3. Cabometyx: Exelixis Inc.
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Product Profile
13. OTHER PROMISING CANDIDATES
13.1. Milciclib: Tiziana Life Sciences
13.1.1. Product Description
13.1.2. Other Developmental Activities
13.1.3. Clinical Development
13.1.4. Safety and Efficacy
13.1.5. Product Profile
13.2. Capmatinib: Eli Lilly and Co.
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.2.5. Product Profile
13.3. Palbociclib: Pfizer
13.3.1. Product Description
13.3.2. Clinical Development
13.3.3. Safety and Efficacy
13.3.4. Product Profile
13.4. ENMD2076: CASI Pharmaceuticals
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Safety and Efficacy
13.4.5. Product Profile
14. FAILURE IN PHASE III CLINICAL TRIALS FOR HEPATOCELLULAR CARCINOMA
15. HEPATOCELLULAR CARCINOMA [HCC]: G8 COUNTRIES MARKET ANALYSIS
16. KEY FINDINGS
16.1. Total Market Size of Hepatocellular Carcinoma (HCC) in G8 Countries
16.2. G8 Countries Market Size of HCC by Line of Therapies
16.3. G8 Countries Market Size of HCC by Therapies
17. MARKET OUTLOOK BY COUNTRY
17.1. The United States: Market Outlook
17.1.1. United States Market Size
17.1.2. Total Market size of Hepatocellular carcinoma [HCC]
17.1.3. Hepatocellular Carcinoma Market Size by Line of Therapies
17.1.4. Market Size by First Line of Therapies
17.1.5. Market Size by Second Line of Therapies
17.2. EU-5 Countries: Market Outlook
17.3. Germany
17.3.1. Total Market size of Hepatocellular Carcinoma
17.3.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.3.3. Market Size by First Line of Therapies
17.3.4. Market Size by Second Line of Therapies
17.4. France
17.4.1. Total Market size of Hepatocellular Carcinoma
17.4.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.4.3. Market Size by First Line of Therapies
17.4.4. Market Size by Second Line of Therapies
17.5. Italy
17.5.1. Total Market size of Hepatocellular Carcinoma
17.5.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.5.3. Market Size by First Line of Therapies
17.5.4. Market Size by Second Line of Therapies
17.6. Spain
17.6.1. Total Market size of Hepatocellular Carcinoma
17.6.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.6.3. Market Size by First Line of Therapies
17.6.4. Market Size by Second Line of Therapies
17.7. United Kingdom
17.7.1. Total Market size of Hepatocellular Carcinoma
17.7.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.7.3. Market Size by First Line of Therapies
17.7.4. Market Size by Second Line of Therapies
17.8. Japan: Market Outlook
17.8.1. Total Market size of Hepatocellular Carcinoma
17.8.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.8.3. Market Size by First Line of Therapies
17.8.4. Market Size by Second Line of Therapies
17.9. China: Market Outlook
17.9.1. Total Market size of Hepatocellular Carcinoma
17.9.2. Hepatocellular Carcinoma Market Size by Line of Therapies
17.9.3. Market Size by First Line of Therapies
17.9.4. Market Size by Second Line of Therapies
18. MARKET DRIVERS
19. MARKET BARRIERS
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Sources Used
22. DELVEINSIGHT CAPABILITIES
23. DISCLAIMER
24. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Molecular targeted therapies under evaluation in Phase II or III randomized controlled trials in HCC
Table 2: Total Incident Cases of HCC in G8 countries (2016-2027)
Table 3: Total Diagnosed Advanced HCC cases in G8 (2016-2027)
Table 4: Total Patients on First-Line Therapies in G8 (2016-2027)
Table 5: Total Patients on Second-Line Therapies in G8 (2016-2027)
Table 6: Total Incident Cases of HCC in the United States (2016-2027)
Table 7: Total Diagnosed Advanced HCC cases in the United States (2016-2027)
Table 8: Total Patients on Therapies in the United States (2016-2027)
Table 9: Patients By Line of Therapies in the United States (2016-2027)
Table 10: Total Incident Cases of HCC in Germany (2016-2027)
Table 11: Total Diagnosed Advanced HCC cases in Germany (2016-2027)
Table 12: Total Patients on Therapies in Germany (2016-2027)
Table 13: Patients By Line of Therapies in Germany (2016-2027)
Table 14: Total Incident Cases of HCC in France (2016-2027)
Table 15: Total Diagnosed Advanced HCC cases in France (2016-2027)
Table 16: Total Patients on Therapies in France (2016-2027)
Table 17: Patients by Line of Therapies in France (2016-2027)
Table 18: Total Incident Cases of HCC in Italy (2016-2027)
Table 19: Total Diagnosed Advanced HCC cases in Italy 2016-2027)
Table 20: Total Patients on Therapies in Italy (2016-2027)
Table 21: Patients By Line of Therapies in the Italy (2016-2027)
Table 22: Total Incident Cases of HCC in the Spain (2016-2027)
Table 23: Total Diagnosed Advanced HCC cases in the Spain (2016-2027)
Table 24: Total Patients on Therapies in the Spain (2016-2027)
Table 25: Patients By Line of Therapies in the Spain (2016-2027)
Table 26: Total Incident Cases of HCC in the United Kingdom (2016-2027)
Table 27: Total Diagnosed Advanced HCC cases in the United Kingdom (2016-2027)
Table 28: Total Patients on Therapies in the United Kingdom (2016-2027)
Table 29: Patients By Line of Therapies in the United Kingdom (2016-2027)
Table 30: Total Incident Cases of HCC in Japan (2016-2027)
Table 31: Total Diagnosed Advanced HCC cases in Japan (2016-2027)
Table 32: Total Patients on Therapies in Japan (2016-2027)
Table 33: Patients By Line of Therapies in Japan (2016-2027)
Table 34: Total Incident Cases of HCC in China (2016-2027)
Table 35: Total Diagnosed Advanced HCC cases in China (2016-2027)
Table 36: Total Patients on Therapies in China (2016-2027)
Table 37: Patients By Line of Therapies in China (2016-2027)
Table 38: Nexavar, Clinical Trial Description, 2018
Table 39: Miriplatin, Clinical Trial Description, 2018
Table 40: Opdivo Clinical Trial Description, 2018
Table 41: Regorafenib, Clinical Trial Description, 2018
Table 42: Lenvima, Clinical Trial Description, 2018
Table 43: G8 Countries Market Size of HCC in USD Million (2016-2027)
Table 44: G8 Countries HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 45: Total Market size of HCC by Therapies in G8 Countries, USD Million (2016-2027)
Table 46: The US Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 47: The U.S. HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 48: The US HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 49: The US HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 50: Germany Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 51: Germany HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 52: Germany HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 53: Germany HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 54: France Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 55: France HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 56: France HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 57: France HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 58: Italy Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 59: Italy HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 60: Italy HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 61: Italy HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 62: Spain Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 63: Spain HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 64: The Spain HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 65: The Spain HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 66: The UK Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 67: The UK HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 68: The UK HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 69: The UK HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 70: Japan Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 71: Japan HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 72: Japan HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 73: Japan HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 74: The China Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 75: China HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 76: China HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 77: China HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 1: Molecular targeted therapies under evaluation in Phase II or III randomized controlled trials in HCC
Table 2: Total Incident Cases of HCC in G8 countries (2016-2027)
Table 3: Total Diagnosed Advanced HCC cases in G8 (2016-2027)
Table 4: Total Patients on First-Line Therapies in G8 (2016-2027)
Table 5: Total Patients on Second-Line Therapies in G8 (2016-2027)
Table 6: Total Incident Cases of HCC in the United States (2016-2027)
Table 7: Total Diagnosed Advanced HCC cases in the United States (2016-2027)
Table 8: Total Patients on Therapies in the United States (2016-2027)
Table 9: Patients By Line of Therapies in the United States (2016-2027)
Table 10: Total Incident Cases of HCC in Germany (2016-2027)
Table 11: Total Diagnosed Advanced HCC cases in Germany (2016-2027)
Table 12: Total Patients on Therapies in Germany (2016-2027)
Table 13: Patients By Line of Therapies in Germany (2016-2027)
Table 14: Total Incident Cases of HCC in France (2016-2027)
Table 15: Total Diagnosed Advanced HCC cases in France (2016-2027)
Table 16: Total Patients on Therapies in France (2016-2027)
Table 17: Patients by Line of Therapies in France (2016-2027)
Table 18: Total Incident Cases of HCC in Italy (2016-2027)
Table 19: Total Diagnosed Advanced HCC cases in Italy 2016-2027)
Table 20: Total Patients on Therapies in Italy (2016-2027)
Table 21: Patients By Line of Therapies in the Italy (2016-2027)
Table 22: Total Incident Cases of HCC in the Spain (2016-2027)
Table 23: Total Diagnosed Advanced HCC cases in the Spain (2016-2027)
Table 24: Total Patients on Therapies in the Spain (2016-2027)
Table 25: Patients By Line of Therapies in the Spain (2016-2027)
Table 26: Total Incident Cases of HCC in the United Kingdom (2016-2027)
Table 27: Total Diagnosed Advanced HCC cases in the United Kingdom (2016-2027)
Table 28: Total Patients on Therapies in the United Kingdom (2016-2027)
Table 29: Patients By Line of Therapies in the United Kingdom (2016-2027)
Table 30: Total Incident Cases of HCC in Japan (2016-2027)
Table 31: Total Diagnosed Advanced HCC cases in Japan (2016-2027)
Table 32: Total Patients on Therapies in Japan (2016-2027)
Table 33: Patients By Line of Therapies in Japan (2016-2027)
Table 34: Total Incident Cases of HCC in China (2016-2027)
Table 35: Total Diagnosed Advanced HCC cases in China (2016-2027)
Table 36: Total Patients on Therapies in China (2016-2027)
Table 37: Patients By Line of Therapies in China (2016-2027)
Table 38: Nexavar, Clinical Trial Description, 2018
Table 39: Miriplatin, Clinical Trial Description, 2018
Table 40: Opdivo Clinical Trial Description, 2018
Table 41: Regorafenib, Clinical Trial Description, 2018
Table 42: Lenvima, Clinical Trial Description, 2018
Table 43: G8 Countries Market Size of HCC in USD Million (2016-2027)
Table 44: G8 Countries HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 45: Total Market size of HCC by Therapies in G8 Countries, USD Million (2016-2027)
Table 46: The US Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 47: The U.S. HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 48: The US HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 49: The US HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 50: Germany Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 51: Germany HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 52: Germany HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 53: Germany HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 54: France Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 55: France HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 56: France HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 57: France HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 58: Italy Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 59: Italy HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 60: Italy HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 61: Italy HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 62: Spain Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 63: Spain HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 64: The Spain HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 65: The Spain HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 66: The UK Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 67: The UK HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 68: The UK HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 69: The UK HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 70: Japan Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 71: Japan HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 72: Japan HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 73: Japan HCC market size by Second Line of Therapies in USD Million (2016-2027)
Table 74: The China Market Hepatocellular Carcinoma in USD Million (2016-2027)
Table 75: China HCC Market Size by Line of therapies in USD Million (2016-2027)
Table 76: China HCC market size by First Line of Therapies in USD Million (2016-2027)
Table 77: China HCC market size by Second Line of Therapies in USD Million (2016-2027)
LIST OF FIGURES
Figure 1: BCLC staging system and therapeutic strategy
Figure 2: Cancer progression and driver genes
Figure 3: Molecular targeted therapies for HCC and their target Signaling pathways
Figure 4: AASLD practice guidelines for HCC surveillance and diagnosis
Figure 5: EASL-EORTC practice guidelines for HCC surveillance and diagnosis
Figure 6: Japanese evidence-based clinical practice guidelines for HCC: surveillance and diagnostic algorithm
Figure 7:NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines for Diagnosis
Figure 8:NCCN Clinical practice Guidelines – When HCC is confirmed
Figure 9: Total Incident Cases of HCC in G8 countries (2016-2027)
Figure 10: Total Diagnosed Advanced HCC cases in G8 countries (2016-2027)
Figure 11: Total Patients on First-Line Therapies in the G8 (2016-2027)
Figure 12: Total Patients on Second-Line Therapies in the G8 (2016-2027)
Figure 13: Total Incident Cases of HCC in the United States (2016-2027)
Figure 14: Total Diagnosed Advanced HCC cases in the United States (2016-2027)
Figure 15: Total Patients on Therapies in the United States (2016-2027)
Figure 16: Patients by Line of Therapies in the United States (2016-2027)
Figure 17: Total Incident Cases of HCC in Germany (2016-2027)
Figure 18: Total Diagnosed Advanced HCC cases in Germany (2016-2027)
Figure 19: Total Patients on Therapies in Germany (2016-2027)
Figure 20: Patients by Line of Therapies in Germany (2016-2027)
Figure 21: Total Incident Cases of HCC in France (2016-2027)
Figure 22: Total Diagnosed Advanced HCC cases in France (2016-2027)
Figure 23: Total Patients on Therapies in France (2016-2027)
Figure 24: Patients by Line of Therapies in France (2016-2027)
Figure 25: Total Incident Cases of HCC in Italy (2016-2027)
Figure 26: Total Diagnosed Advanced HCC cases in Italy (2016-2027)
Figure 27: Total Patients on Therapies in Italy (2016-2027)
Figure 28: Patients by Line of Therapies in the Italy (2016-2027)
Figure 29: Total Incident Cases of HCC in the Spain (2016-2027)
Figure 30: Total Diagnosed Advanced HCC cases in Spain (2016-2027)
Figure 31: Total Patients on Therapies in Spain (2016-2027)
Figure 32: Patients By Line of Therapies in Spain (2016-2027)
Figure 33: Total Incident Cases of HCC in the United Kingdom (2016-2027)
Figure 34: Total Diagnosed Advanced HCC cases in the United Kingdom (2016-2027)
Figure 35: Total Patients on Therapies in the United Kingdom (2016-2027)
Figure 36: Patients By Line of Therapies in the United Kingdom (2016-2027)
Figure 37: Total Incident Cases of HCC in Japan (2016-2027)
Figure 38: Total Diagnosed Advanced HCC cases in Japan (2016-2027)
Figure 39: Total Patients on Therapies in Japan (2016-2027)
Figure 40: Patients By Line of Therapies in Japan (2016-2027)
Figure 41: Total Incident Cases of HCC in China (2016-2027)
Figure 42: Total Diagnosed Advanced HCC cases in China (2016-2027)
Figure 43: Total Patients on Therapies in China (2016-2027)
Figure 44: Patients by Line of Therapies in China (2016-2027)
Figure 45:NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines for Diagnosis
Figure 46:Treatment algorithm according to NCC guidelines
Figure 47: Unmet Needs for Hepatocellular Carcinoma
Figure 48: G8 Countries Market Size of HCC in USD Million (2016-2027)
Figure 49: G8 Countries Market Size of HCC by Line of Therapies in USD Million (2016-2027)
Figure 50: Total Market size of HCC by Therapies in G8 Countries, USD Million (2016-2027)
Figure 51: Market Size of HCC in the United States, USD Millions (2016-2027)
Figure 52: The U.S. HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 53: The U.S. market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 54: The U.S. market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 55: Market Size of HCC in Germany, USD Millions (2016-2027)
Figure 56: Germany HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 57: Germany market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 58: Germany market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 59: Market Size of HCC in France, USD Millions (2016-2027)
Figure 60: France HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 61: France market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 62: France market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 63: Market Size of HCC in Italy, USD Millions (2016-2027)
Figure 64: Italy HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 65: Italy market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 66: Italy market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 67: Market Size of HCC in Spain, USD Millions (2016-2027)
Figure 68: Spain HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 69: Spain market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 70: Spain market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 71: Market Size of HCC in UK, USD Millions (2016-2027)
Figure 72: The UK HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 73: The UK market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 74: The UK market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 75: Market Size of HCC in Japan, USD Millions (2016-2027)
Figure 76: Japan HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 77: Japan market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 78: Japan market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 79: Market Size of HCC in China, USD Millions (2016-2027)
Figure 80: China HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 81: China market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 82: China market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 83: Market Drivers for Hepatocellular Carcinoma
Figure 84: Market Barriers for Hepatocellular Carcinoma
Figure 1: BCLC staging system and therapeutic strategy
Figure 2: Cancer progression and driver genes
Figure 3: Molecular targeted therapies for HCC and their target Signaling pathways
Figure 4: AASLD practice guidelines for HCC surveillance and diagnosis
Figure 5: EASL-EORTC practice guidelines for HCC surveillance and diagnosis
Figure 6: Japanese evidence-based clinical practice guidelines for HCC: surveillance and diagnostic algorithm
Figure 7:NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines for Diagnosis
Figure 8:NCCN Clinical practice Guidelines – When HCC is confirmed
Figure 9: Total Incident Cases of HCC in G8 countries (2016-2027)
Figure 10: Total Diagnosed Advanced HCC cases in G8 countries (2016-2027)
Figure 11: Total Patients on First-Line Therapies in the G8 (2016-2027)
Figure 12: Total Patients on Second-Line Therapies in the G8 (2016-2027)
Figure 13: Total Incident Cases of HCC in the United States (2016-2027)
Figure 14: Total Diagnosed Advanced HCC cases in the United States (2016-2027)
Figure 15: Total Patients on Therapies in the United States (2016-2027)
Figure 16: Patients by Line of Therapies in the United States (2016-2027)
Figure 17: Total Incident Cases of HCC in Germany (2016-2027)
Figure 18: Total Diagnosed Advanced HCC cases in Germany (2016-2027)
Figure 19: Total Patients on Therapies in Germany (2016-2027)
Figure 20: Patients by Line of Therapies in Germany (2016-2027)
Figure 21: Total Incident Cases of HCC in France (2016-2027)
Figure 22: Total Diagnosed Advanced HCC cases in France (2016-2027)
Figure 23: Total Patients on Therapies in France (2016-2027)
Figure 24: Patients by Line of Therapies in France (2016-2027)
Figure 25: Total Incident Cases of HCC in Italy (2016-2027)
Figure 26: Total Diagnosed Advanced HCC cases in Italy (2016-2027)
Figure 27: Total Patients on Therapies in Italy (2016-2027)
Figure 28: Patients by Line of Therapies in the Italy (2016-2027)
Figure 29: Total Incident Cases of HCC in the Spain (2016-2027)
Figure 30: Total Diagnosed Advanced HCC cases in Spain (2016-2027)
Figure 31: Total Patients on Therapies in Spain (2016-2027)
Figure 32: Patients By Line of Therapies in Spain (2016-2027)
Figure 33: Total Incident Cases of HCC in the United Kingdom (2016-2027)
Figure 34: Total Diagnosed Advanced HCC cases in the United Kingdom (2016-2027)
Figure 35: Total Patients on Therapies in the United Kingdom (2016-2027)
Figure 36: Patients By Line of Therapies in the United Kingdom (2016-2027)
Figure 37: Total Incident Cases of HCC in Japan (2016-2027)
Figure 38: Total Diagnosed Advanced HCC cases in Japan (2016-2027)
Figure 39: Total Patients on Therapies in Japan (2016-2027)
Figure 40: Patients By Line of Therapies in Japan (2016-2027)
Figure 41: Total Incident Cases of HCC in China (2016-2027)
Figure 42: Total Diagnosed Advanced HCC cases in China (2016-2027)
Figure 43: Total Patients on Therapies in China (2016-2027)
Figure 44: Patients by Line of Therapies in China (2016-2027)
Figure 45:NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines for Diagnosis
Figure 46:Treatment algorithm according to NCC guidelines
Figure 47: Unmet Needs for Hepatocellular Carcinoma
Figure 48: G8 Countries Market Size of HCC in USD Million (2016-2027)
Figure 49: G8 Countries Market Size of HCC by Line of Therapies in USD Million (2016-2027)
Figure 50: Total Market size of HCC by Therapies in G8 Countries, USD Million (2016-2027)
Figure 51: Market Size of HCC in the United States, USD Millions (2016-2027)
Figure 52: The U.S. HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 53: The U.S. market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 54: The U.S. market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 55: Market Size of HCC in Germany, USD Millions (2016-2027)
Figure 56: Germany HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 57: Germany market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 58: Germany market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 59: Market Size of HCC in France, USD Millions (2016-2027)
Figure 60: France HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 61: France market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 62: France market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 63: Market Size of HCC in Italy, USD Millions (2016-2027)
Figure 64: Italy HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 65: Italy market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 66: Italy market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 67: Market Size of HCC in Spain, USD Millions (2016-2027)
Figure 68: Spain HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 69: Spain market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 70: Spain market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 71: Market Size of HCC in UK, USD Millions (2016-2027)
Figure 72: The UK HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 73: The UK market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 74: The UK market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 75: Market Size of HCC in Japan, USD Millions (2016-2027)
Figure 76: Japan HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 77: Japan market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 78: Japan market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 79: Market Size of HCC in China, USD Millions (2016-2027)
Figure 80: China HCC Market Size by Line of therapies in USD Million (2016-2027)
Figure 81: China market size of HCC by First Line of therapies in USD Million (2016-2027)
Figure 82: China market size of HCC by Second Line of therapies in USD Million (2016-2027)
Figure 83: Market Drivers for Hepatocellular Carcinoma
Figure 84: Market Barriers for Hepatocellular Carcinoma
